BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) posted its earnings results on Monday. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.39), Zacks reports.
BriaCell Therapeutics Stock Down 4.7 %
BCTX stock opened at $3.88 on Wednesday. The company’s 50-day simple moving average is $4.67 and its 200-day simple moving average is $9.00. BriaCell Therapeutics has a 52-week low of $3.00 and a 52-week high of $45.45. The firm has a market cap of $14.39 million, a P/E ratio of -0.29 and a beta of 1.71.
Wall Street Analyst Weigh In
Separately, HC Wainwright boosted their target price on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- Delta’s Stock Takes a Hit—Can Lower Oil Prices Fuel a Comeback?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Hot Stock Upgrades as Analysts Look Ahead to Q2 Earnings
- Energy and Oil Stocks Explained
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
